Oncotelic Therapeutics, Inc. OTLC
We take great care to ensure that the data presented and summarized in this overview for Oncotelic Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OTLC
Top Purchases
Top Sells
About OTLC
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Insider Transactions at OTLC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 23
2024
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
500,000
+0.54%
|
$0
$0.02 P/Share
|
|
Jun 29
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
425,000
+0.46%
|
$0
$0.02 P/Share
|
|
Jun 28
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
75,000
+0.08%
|
$0
$0.03 P/Share
|
|
Jun 16
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+0.11%
|
$0
$0.03 P/Share
|
|
Jun 14
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
400,000
+0.44%
|
$0
$0.03 P/Share
|
|
May 26
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
126,888
+0.14%
|
$0
$0.03 P/Share
|
|
May 02
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+0.11%
|
$0
$0.04 P/Share
|
|
Dec 06
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
120,000
+0.13%
|
$0
$0.05 P/Share
|
|
Nov 22
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
70,000
+0.08%
|
$0
$0.08 P/Share
|
|
Sep 26
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.02%
|
$0
$0.07 P/Share
|
|
Aug 25
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
80,000
+0.09%
|
$0
$0.08 P/Share
|
|
Jul 08
2021
|
Amit B. Shah CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
298,837
+45.44%
|
-
|
|
Jul 08
2021
|
Saran Saund Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
102,519
+0.62%
|
-
|
|
Jul 08
2021
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
259,302
+0.29%
|
-
|
|
Mar 31
2021
|
Saran Saund Chief Business Officer |
BUY
Conversion of derivative security
|
Direct |
16,354,961
+50.0%
|
-
|
|
Mar 31
2021
|
Steven W King Director |
BUY
Conversion of derivative security
|
Indirect |
3,291,720
+49.71%
|
-
|
|
Mar 31
2021
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Conversion of derivative security
|
Indirect |
19,521,186
+45.22%
|
-
|
|
Mar 31
2021
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Conversion of derivative security
|
Direct |
74,455,719
+45.2%
|
-
|
|
Mar 31
2021
|
Anthony E Maida Iii Chief Clin. Ops. Officer |
BUY
Conversion of derivative security
|
Direct |
938,646
+45.22%
|
-
|
|
Nov 24
2020
|
Amit B. Shah CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
8,220
+12.05%
|
$0
$0.19 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 500K shares |
|---|